Financial
FY2025 revenue $2.23bn (-6.3%); operating margin 1.9%; net income $0.7m.
Cash $308.0m; debt $1.28bn.
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
FY2025 revenue $2.23bn (-6.3%); operating margin 1.9%; net income $0.7m.
Cash $308.0m; debt $1.28bn.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$2.2bn | -6.3% | US$42.8m | US$700k | ICU Medical |
Products not yet catalogued.
FY2025 revenue $2.23bn (-6.3%); operating margin 1.9%; net income $0.7m.
Cash $308.0m; debt $1.28bn.
May 2025: ICU Medical and Otsuka Pharmaceutical Factory completed formation of the Otsuka ICU Medical IV solutions joint venture for North America. Apr 2025: ICU Medical received an FDA warning letter (see regulatory).
No data breaches, cyber incidents, regulator action or published product security advisories involving ICU Medical found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Aug 2025: FDA classed a Plum Duo infusion pump software correction (pump may freeze, delaying therapy) as its most serious recall type; no injuries reported. Apr 2025: an FDA warning letter cited unapproved design changes to Medfusion 4000 and CADD Solis pumps.
No notable troubled implementations, terminations, customer disputes or significant NHS contracts involving ICU Medical found in HSH's search of the last 24 months.
No competitors linked yet.